Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 3/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL206 | 0.83 | CYP2C19 (0.56) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5209412 | 0.80 | CYP2C19 (0.54) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7136112 | 0.80 | CYP2C19 (0.54) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5209418 | 0.80 | CYP2C19 (0.54) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7029336 | 0.80 | CYP2C19 (0.55) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL11389034 | 0.79 | CYP2C19 (0.48) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3078147 | 0.78 | CYP2C19 (0.64) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL11465830 | 0.78 | CYP2C19 (0.56) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8541503 | 0.78 | CYP2C19 (0.52) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL7138153 | 0.78 | CYP2C19 (0.56) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116322094-A | Perovskite solar cell passivated by sulfur-containing passivating agent | 陕西师范大学 | 2023-06-23 | — | — | CN | claimed |
| EP-4676926-A1 | BICYCLIC HETEROARYL COMPOUNDS FOR USE AS GPR35 MODULATORS | ThirtyFiveBio Limited (GB) | 2026-01-14 | — | — | EP | disclosed |
| CN-119136619-A | Perovskite solar cell and chemical induction surface reconstruction preparation method | 陕西师范大学 | 2024-12-13 | — | — | CN | disclosed |
| WO-2024184650-A1 | BICYCLIC HETEROARYL COMPOUNDS FOR USE AS GPR35 MODULATORS. | ThirtyFiveBio Limited (GB) | 2024-09-12 | — | — | WO | disclosed |
| US-20240009153-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROPRO THERAPEUTICS, INC. | 2024-01-11 | — | — | US | disclosed |
| CN-116322094-A | Perovskite solar cell passivated by sulfur-containing passivating agent | 陕西师范大学 | 2023-06-23 | — | — | CN | disclosed |
| US-20220071935-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROPRO THERAPEUTICS, INC. | 2022-03-10 | — | — | US | disclosed |
| US-20190151263-A1 | BUMETANIDE ANALGOS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2019-05-23 | — | — | US | disclosed |
| EP-3006449-B1 | METHOD FOR SYNTHESIZING OPTICALLY ACTIVE ALPHA-AMINO ACID USING CHIRAL METAL COMPLEX COMPRISING AXIALLY CHIRAL N-(2-ACYLARYL)-2-[5,7-DIHYDRO-6H-DIBENZO[C,E]AZEPIN-6-YL]ACETAMIDE COMPOUND AND AMINO ACID | HAMARI CHEMICALS LTD (JP) | 2018-01-31 | — | — | EP | disclosed |
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2017-08-31 | — | — | US | disclosed |
| US-4309428-A | Maytansinoids | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1982-01-05 | — | — | US | disclosed |
| EP-0025496-A1 | Maytansinoids, their production and therapeutic compositions containing them | Takeda Chemical Industries, Ltd. (JP) | 1981-03-25 | — | — | EP | disclosed |
| US-4169849-A | 11-DESOXY-15-THIAPROSTAGLANDINS | PFIZER INC. (US) | 1979-10-02 | — | — | US | disclosed |
| US-4154840-A | Antihypertensive pipecolic acid derivatives | E. R. SQUIBB & SONS, INC. (US) | 1979-05-15 | — | — | US | disclosed |
| US-4148804-A | ANTIULCER AGENTS, SELECTIVITY | PFIZER INC. (US) | 1979-04-10 | — | — | US | disclosed |
| US-4129728-A | ANTIULCER | PFIZER INC. (US) | 1978-12-12 | — | — | US | disclosed |
| US-4105776-A | ANGIOTENSIN CONVERTING ENZYME INHIBITORS, HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1978-08-08 | — | — | US | disclosed |
| US-4092349-A | ANTIULCER AGENTS | PFIZER INC. (US) | 1978-05-30 | — | — | US | disclosed |
| US-3988375-A | HERBICIDES | MONSANTO COMPANY (US) | 1976-10-26 | — | — | US | disclosed |
| US-3974031-A | Process for producing L-cysteine or its derivatives | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JA) | 1976-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240009153-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | CYP2C19 656/4885CYP1A2 910/4885CYP3A4 733/4885 |
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | CYP2C19 629/4885CYP1A2 936/4885CYP3A4 726/4885 |
| US-20220071935-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | CYP2C19 656/4885CYP1A2 910/4885CYP3A4 733/4885 |
| US-20190151263-A1 | BUMETANIDE ANALGOS, COMPOSITIONS, AND METHODS OF USE | SLC6A1, SLC6A11, SLC6A13 | CYP2C19 638/4885CYP1A2 746/4885CYP3A4 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.